151 related articles for article (PubMed ID: 34499741)
1. It's more than just cancer biology: Health disparities in patients with pancreatic neuroendocrine tumors.
Underwood PW; Riner AN; Neal D; Cameron ME; Yakovenko A; Reddy S; Rose JB; Hughes SJ; Trevino JG
J Surg Oncol; 2021 Dec; 124(8):1390-1401. PubMed ID: 34499741
[TBL] [Abstract][Full Text] [Related]
2. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes.
Riner AN; Underwood PW; Yang K; Herremans KM; Cameron ME; Chamala S; Qiu P; George TJ; Permuth JB; Merchant NB; Trevino JG
Cancer Med; 2020 Jun; 9(12):4069-4082. PubMed ID: 32285629
[TBL] [Abstract][Full Text] [Related]
3. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival.
Heller DR; Nicolson NG; Ahuja N; Khan S; Kunstman JW
JAMA Surg; 2020 Feb; 155(2):e195047. PubMed ID: 31800002
[TBL] [Abstract][Full Text] [Related]
4. Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study.
Zhou H; Zhang Y; Wei X; Yang K; Tan W; Qiu Z; Li S; Chen Q; Song Y; Gao S
Cancer Med; 2017 Nov; 6(11):2745-2756. PubMed ID: 28980417
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
6. Differences in outcome for patients with cholangiocarcinoma: Racial/ethnic disparity or socioeconomic factors?
Lee RM; Liu Y; Gamboa AC; Staley CA; Kooby D; Russell MC; Cardona K; Maithel SK
Surg Oncol; 2020 Sep; 34():126-133. PubMed ID: 32891317
[TBL] [Abstract][Full Text] [Related]
7. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity.
Swords DS; Mulvihill SJ; Brooke BS; Skarda DE; Firpo MA; Scaife CL
Surgery; 2019 Apr; 165(4):751-759. PubMed ID: 30551868
[TBL] [Abstract][Full Text] [Related]
8. Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma.
Chen HY; Zhang XY; Deng XY; Ge YL; Tang YQ; Cui H; Yang B; Pan Y; Shi D; Yu RS
AJR Am J Roentgenol; 2020 Aug; 215(2):390-397. PubMed ID: 32432906
[No Abstract] [Full Text] [Related]
9. Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?
Lee RM; Liu Y; Gamboa AC; Zaidi MY; Kooby DA; Shah MM; Cardona K; Russell MC; Maithel SK
J Surg Oncol; 2019 Sep; 120(4):611-623. PubMed ID: 31301148
[TBL] [Abstract][Full Text] [Related]
10. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma.
Mitsakos AT; Dennis SO; Parikh AA; Snyder RA
J Surg Oncol; 2021 Mar; 123(4):970-977. PubMed ID: 33497474
[TBL] [Abstract][Full Text] [Related]
11. Racial Differences in Gastroenteropancreatic Neuroendocrine Tumor Treatment and Survival in the United States.
Kessel E; Naparst M; Alpert N; Diaz K; Ahn E; Wolin E; Taioli E; Kim MK
Pancreas; 2021 Jan; 50(1):29-36. PubMed ID: 33370020
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Impact of Tumor Size on Pancreatic Neuroendocrine Tumor Recurrence May Have Racial Variance.
Zheng-Pywell R; Fang A; AlKashash A; Awad S; Reddy S; Vickers S; Heslin M; Dudeja V; Chen H; Rose JB
Pancreas; 2021 Mar; 50(3):347-352. PubMed ID: 33835965
[TBL] [Abstract][Full Text] [Related]
13. Clinical Characteristics and Prognostic Factors of Early-Onset Pancreatic Neuroendocrine Tumors.
Shi M; Zhou B
Cancer Control; 2021; 28():1073274820986827. PubMed ID: 33491476
[TBL] [Abstract][Full Text] [Related]
14. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
Karmazanovsky G; Belousova E; Schima W; Glotov A; Kalinin D; Kriger A
Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
[TBL] [Abstract][Full Text] [Related]
15. Associations of gender, race, and ethnicity with disparities in short-term adverse outcomes after pancreatic resection for cancer.
Pastrana Del Valle J; Mahvi DA; Fairweather M; Wang J; Clancy TE; Ashley SW; Urman RD; Whang EE; Gold JS
J Surg Oncol; 2022 Mar; 125(4):646-657. PubMed ID: 34786728
[TBL] [Abstract][Full Text] [Related]
16. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of multidetector CT features in predicting overall survival outcomes in patients with pancreatic neuroendocrine tumors.
Yang B; Chen HY; Zhang XY; Pan Y; Lu YF; Yu RS
Eur J Radiol; 2020 Mar; 124():108847. PubMed ID: 31991300
[TBL] [Abstract][Full Text] [Related]
18. Multifocality is not associated with worse survival in sporadic pancreatic neuroendocrine tumors.
Gudmundsdottir H; Graham RP; Sonbol MB; Smoot RL; Truty MJ; Kendrick ML; Nagorney DM; Habermann EB; Halfdanarson TR; Cleary SP
J Surg Oncol; 2021 Dec; 124(7):1077-1084. PubMed ID: 34310723
[TBL] [Abstract][Full Text] [Related]
19. Ethnic and racial disparities of pancreatic adenocarcinoma in Florida.
Fagenson AM; Grossi SM; Musgrove K; Solomon N; de la Vega PR; Castro G; Pitt HA; Varella M; Zavallos J; Acuna J
HPB (Oxford); 2020 May; 22(5):735-743. PubMed ID: 31601507
[TBL] [Abstract][Full Text] [Related]
20. Racial and Socioeconomic Disparities in Mantle Cell Lymphoma.
Shah NN; Xi Y; Liu Y; Koff JL; Flowers CR; Behera M; Cohen JB
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e312-e320. PubMed ID: 31029647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
